NLP for Adverse Event Coding: Accuracy, Speed, and Regulatory Defensibility

Adverse event narrative coding is one of the most labor-intensive processes in clinical drug development. A large Phase III trial can generate tens of thousands of adverse event narratives — free-text descriptions of clinical events that must be coded to MedDRA preferred terms and system organ classes before they can be analyzed, reported, and submitted to regulatory authorities.

Manual coding is slow, expensive, and inconsistent. Different coders apply MedDRA terms differently. Coding conventions evolve across MedDRA versions. The same verbatim term can map to different preferred terms depending on clinical context. The result is a process that is both a bottleneck and a source of data quality risk.

Natural language processing offers a path to faster, more consistent adverse event coding. But NLP in a pharmacovigilance context is not a generic text processing problem. It requires models that understand clinical language, MedDRA hierarchy, and the regulatory standards that govern adverse event reporting.

General-purpose NLP models — even large language models trained on broad text corpora — perform poorly on clinical adverse event narratives without domain-specific fine-tuning. Clinical language is dense with abbreviations, negations, temporal qualifiers, and domain-specific terminology that general models misinterpret.

A narrative that reads "patient experienced mild, transient elevation in ALT, resolved without intervention" requires a model that understands:

• "ALT elevation" maps to a specific MedDRA preferred term (Alanine aminotransferase increased)
• "Mild" and "transient" are severity and duration qualifiers, not separate events
• "Resolved without intervention" is a resolution qualifier, not a new event
• The overall narrative describes a single adverse event, not multiple

Models trained on biomedical corpora — BioBERT, ClinicalBERT, and their successors — perform substantially better on clinical text than general-purpose models. Fine-tuning on adverse event narratives with MedDRA annotations improves performance further. At Bracy Analytics, our NLP models are trained and validated specifically for adverse event coding, with performance benchmarks that meet the accuracy thresholds required for regulatory use.

No NLP model achieves 100% accuracy on adverse event coding. The question is not whether to use human review, but how to design the human-in-the-loop workflow to maximize efficiency while maintaining the accuracy and audit trail that regulatory review requires.

The approach we use is confidence-stratified review. The NLP model assigns a confidence score to each coding suggestion. High-confidence suggestions — typically 85-90% of narratives in a well-trained model — are reviewed by a medical coder who confirms or overrides the suggestion. Low-confidence suggestions receive more intensive review, with the coder making the primary coding decision.

This approach concentrates human review where it adds the most value: on the ambiguous cases where clinical judgment is genuinely required. For a 50,000-narrative dataset, this can reduce the time required for human review by 70-80% compared to fully manual coding — while maintaining the accuracy and documentation standards that pharmacovigilance requires.

Every coding decision in a pharmacovigilance database must be auditable. Regulators need to be able to trace each MedDRA code back to the verbatim term, the coding rationale, and the coder who made the decision.

NLP-assisted coding must be integrated into this audit trail. The system must record whether each coding decision was made by the NLP model, confirmed by a human reviewer, or overridden by a human reviewer — along with the confidence score, the alternative coding suggestions considered, and the identity of the reviewer.

This is not optional. It is a regulatory requirement. Any NLP implementation that does not produce a complete, auditable coding record is not suitable for use in a pharmacovigilance context, regardless of its accuracy.

The value of NLP in pharmacovigilance extends beyond individual narrative coding. When applied at scale — across a full safety database, a portfolio of studies, or a post-market surveillance program — NLP can identify patterns in adverse event narratives that are not visible in the coded data alone.

Coded MedDRA terms capture the what of an adverse event. The narrative captures the how, the when, the severity, the clinical context, and the resolution. NLP can extract structured information from these narratives at scale — enabling signal detection analyses that incorporate the full richness of the narrative data, not just the coded terms.

This is an emerging application, but one with significant potential for improving the sensitivity and specificity of pharmacovigilance signal detection.

Organizations considering NLP for adverse event coding should evaluate vendors and tools on several dimensions:

Model performance: What accuracy benchmarks has the model achieved on adverse event coding tasks? How was performance measured, and on what data?

MedDRA version currency: MedDRA is updated twice yearly. The NLP model must be updated to reflect current MedDRA terminology and hierarchy.

Audit trail completeness: Does the system produce a complete, auditable record of every coding decision?

Integration with existing workflows: Can the system integrate with the organization's existing safety database and coding workflows, or does it require a separate process?

Validation documentation: Is there validation documentation suitable for regulatory review?

These are not easy questions to answer, and the answers matter. NLP for adverse event coding is a powerful tool — but only when implemented with the rigor that pharmacovigilance demands.